Keywords: Biogen Idec, BG-12, Dimethyl fumarte, Multiple sclerosis. ACTRIMS, ACTRIMS, Alemtuzumab, Daclizumab, Sanofi, Genzyme, Lemtrada

Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif

Article | 24 October 2011

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB) saw its shares jump 6% to $107.53 last Friday, after the company released much anticipated ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in